EPHX2 and obesity due to melanocortin 4 receptor deficiency: These findings support that sEH could be a novel therapeutic target of obesity-associated CRC; sEH inhibitors, which are currently being evaluated in clinical trials targeting other disorders [10, 11], could be promising agents for preventing obesity-associated CRC.